Kidney Cancer Coverage from Every Angle

Recent News

IKCS 2019: Comparing Patient- and Clinician-Reported Performance Status
IKCS 2019: Identifying a New Role for SETD2 in Clear Cell Renal Cell Carcinoma
IKCS 2019: Lenvatinib Plus Pembrolizumab in Subset of Patients With Kidney Cancer
IKCS 2019: Treatment-Free Survival With Immunotherapy Versus Sunitinib in Kidney Cancer
IKCS 2019: Histopathologic Changes Associated With Immunotherapy for Kidney Cancer
Robotic Radiosurgery for Kidney Cancer in Patients With Impaired Renal Function
First-in-Class Pegilodecakin Under Study in Advanced Renal Tumors
Could Virtual Reality Models for Surgical Planning Improve Nephrectomy Outcomes?
ESMO 2019: Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma
ESMO 2019: Enfortumab Vedotin Plus Pembrolizumab in Advanced Bladder Cancer
ESMO 2019: Tailored Approach to Immunotherapy for Advanced Kidney Cancer
Quality Care 2019: Does Comprehensive Genomic Profiling Improve Outcomes in Metastatic Kidney Cancer?
Are Medical Students and Residents Staying Away From Nephrology?
Tubular Progenitor Cells in End-Stage Kidney Disease and Papillary Adenomas
Quality Care 2019: Cost of Treatment Per Episode of Care in Metastatic Kidney Cancer
Studying NR1B2 as Tumor Suppressor in Renal Clear Cell Carcinoma
Urine Metabolic Profiles: Potential Key to Diagnosing Kidney Cancer
Microarray Technology Brings More Precise Diagnosis for Rare Kidney Cancer
Nivolumab for Advanced Renal Cell Carcinoma: 5-Year Survival
Using Immuno-PET to Detect PD-L1 in Renal Cell Carcinoma: Case Report
PTEN Mutation in Clear Cell Renal Cell Carcinoma
Intermittent Nivolumab Dosing for Metastatic Renal Cell Carcinoma
Initiative to Reduce Narcotic Prescribing in Robotic Nephrectomy
Is Immunotherapy With Cytoreductive Surgery Feasible in Metastatic Kidney Cancer?
Atezolizumab Plus Bevacizumab for Sarcomatoid Metastatic Renal Cell Carcinoma
FDA Approves Bevacizumab Biosimilar in Metastatic Renal Cell Carcinoma
ASCO 2019: Trial Update on Cytoreductive Nephrectomy for Intermediate-Risk Metastatic Renal Cancer
ASCO 2019: Enfortumab Vedotin in Advanced Urothelial Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.